CD20/Firefly Luciferase CHO Cell Line

Catalog #

78620

$9,400 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant clonal stable CHO-K1 cell line constitutively expressing both the full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866), and the firefly (Photinus pyralis) luciferase. Surface expression of CD20 was confirmed by flow cytometry.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, CD_antigen: CD20, MS4A1

●

Product Data Gallery

Flow cytometry analysis of CD20 cell surface expression in CD20/Firefly Luciferase CHO Cell Line

Luciferase activity of CD20/Firefly luciferase CHO cells

Product Info

Storage and Usage

Citations

Host Cell Line

CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent

Species

Human

Supplied As

Each vial contains >2 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience, #79796)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium 3	BPS Bioscience #60186
Growth Medium 3A	BPS Bioscience #60188

Genbank #

NM_152866

UniProt #

P11836

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an “Essential Medicine”. Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin’s lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 3 (BPS Bioscience #60186):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3A (BPS Bioscience #60188):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml of Geneticin and 500 μg/ml of Hygromycin.

Applications

Useful for CD20 binding assays to screen for potential CD20 ligands.
Useful as CD20-expressing target cells in co-culture assays with Anti-CD20-CAR-T cells.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles.

Scientific Category

Immunotherapy, CAR-T

Regulatory Status

Research Use Only